Clinical Trial Detail

NCT ID NCT01633970
Title A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Avastin (Bevacizumab) and/or With Chemotherapy in Patients With Locally Advanced or Metastatic Solid Tumors
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements no
Sponsors Genentech
Indications

Advanced Solid Tumor

Therapies

Atezolizumab + Carboplatin + Paclitaxel

Atezolizumab + Carboplatin + Pemetrexed

Atezolizumab + Bevacizumab + Capecitabine

Age Groups: adult

No variant requirements are available.